70 related articles for article (PubMed ID: 20185912)
21. Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping.
Reinhold WC; Kouros-Mehr H; Kohn KW; Maunakea AK; Lababidi S; Roschke A; Stover K; Alexander J; Pantazis P; Miller L; Liu E; Kirsch IR; Urasaki Y; Pommier Y; Weinstein JN
Cancer Res; 2003 Mar; 63(5):1000-11. PubMed ID: 12615715
[TBL] [Abstract][Full Text] [Related]
22. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
Goldwasser F; Bae I; Fornace AJ; Pommier Y
Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer.
Liu Y; Xing H; Weng D; Song X; Qin X; Xia X; Weng Y; Liang F; Chen G; Han X; Ma X; Wang S; Zhou J; Xu G; Meng L; Ma D
Cancer Lett; 2009 Feb; 274(1):47-53. PubMed ID: 18929442
[TBL] [Abstract][Full Text] [Related]
24. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery.
De Angelis PM; Svendsrud DH; Kravik KL; Stokke T
Mol Cancer; 2006 May; 5():20. PubMed ID: 16709241
[TBL] [Abstract][Full Text] [Related]
25. Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth.
Bhonde MR; Hanski ML; Notter M; Gillissen BF; Daniel PT; Zeitz M; Hanski C
Oncogene; 2006 Jan; 25(2):165-75. PubMed ID: 16170360
[TBL] [Abstract][Full Text] [Related]
26. Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy.
Miettinen S; Ylikomi T
Anticancer Drugs; 2009 Aug; 20(7):589-600. PubMed ID: 19491654
[TBL] [Abstract][Full Text] [Related]
27. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
Xu JM; Azzariti A; Tommasi S; Lacalamita R; Colucci G; Johnston PG; Church SW; Paradiso A
Clin Colorectal Cancer; 2002 Nov; 2(3):182-8. PubMed ID: 12482336
[TBL] [Abstract][Full Text] [Related]
28. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.
Motwani M; Sirotnak FM; She Y; Commes T; Schwartz GK
Cancer Res; 2002 Jul; 62(14):3950-5. PubMed ID: 12124325
[TBL] [Abstract][Full Text] [Related]
29. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.
Oizumi S; Isobe H; Ogura S; Ishida T; Yamazaki K; Nishimura M; Kawakami Y; Dosaka-Akita H
Anticancer Res; 2002; 22(6C):4029-37. PubMed ID: 12553028
[TBL] [Abstract][Full Text] [Related]
30. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
[TBL] [Abstract][Full Text] [Related]
31. Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study.
Daoud SS; Munson PJ; Reinhold W; Young L; Prabhu VV; Yu Q; LaRose J; Kohn KW; Weinstein JN; Pommier Y
Cancer Res; 2003 Jun; 63(11):2782-93. PubMed ID: 12782583
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells.
Saga Y; Mizukami H; Suzuki M; Kohno T; Urabe M; Ozawa K; Sato I
Clin Cancer Res; 2002 May; 8(5):1248-52. PubMed ID: 12006545
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells.
Minderman H; Conroy JM; O'Loughlin KL; McQuaid D; Quinn P; Li S; Pendyala L; Nowak NJ; Baer MR
Mol Cancer Ther; 2005 Jun; 4(6):885-900. PubMed ID: 15956246
[TBL] [Abstract][Full Text] [Related]
34. Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells.
Pálmer HG; Sánchez-Carbayo M; Ordóñez-Morán P; Larriba MJ; Cordón-Cardó C; Muñoz A
Cancer Res; 2003 Nov; 63(22):7799-806. PubMed ID: 14633706
[TBL] [Abstract][Full Text] [Related]
35. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
[TBL] [Abstract][Full Text] [Related]
36. Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38.
Hapke G; Yin MB; Wu J; Frank C; Rustum YM
Int J Oncol; 2002 Nov; 21(5):1059-66. PubMed ID: 12370755
[TBL] [Abstract][Full Text] [Related]
37. Cell diameter measurements obtained with a handheld cell counter could be used as a surrogate marker of G2/M arrest and apoptosis in colon cancer cell lines exposed to SN-38.
Tahara M; Inoue T; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
Biochem Biophys Res Commun; 2013 May; 434(4):753-9. PubMed ID: 23583407
[TBL] [Abstract][Full Text] [Related]
38. Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in p53 mutant human colon cancer.
Tanaka K; Inoue Y; Hiro J; Yoshiyama S; Toiyama Y; Eguchi T; Miki C; Kusunoki M
J Exp Clin Cancer Res; 2007 Jun; 26(2):241-51. PubMed ID: 17725105
[TBL] [Abstract][Full Text] [Related]
39. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
Dopeso H; Mateo-Lozano S; Elez E; Landolfi S; Ramos Pascual FJ; Hernández-Losa J; Mazzolini R; Rodrigues P; Bazzocco S; Carreras MJ; Espín E; Armengol M; Wilson AJ; Mariadason JM; Ramon Y Cajal S; Tabernero J; Schwartz S; Arango D
Clin Cancer Res; 2010 Apr; 16(8):2375-82. PubMed ID: 20371676
[TBL] [Abstract][Full Text] [Related]
40. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Ravi R; Jain AJ; Schulick RD; Pham V; Prouser TS; Allen H; Mayer EG; Yu H; Pardoll DM; Ashkenazi A; Bedi A
Cancer Res; 2004 Dec; 64(24):9105-14. PubMed ID: 15604280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
